Get the Stockscreener App
6.43
3.02%
-0.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $6.43, with a volume of 1.64M.
It is down -3.02% in the last 24 hours and down -5.86% over the past month.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$6.63
Open:
$6.72
24h Volume:
1.64M
Relative Volume:
0.61
Market Cap:
$457.33M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.9207
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+0.94%
1M Performance:
-5.86%
6M Performance:
-6.40%
1Y Performance:
-21.78%
1-Day Range:
$6.33
$6.77
1-Week Range:
$6.33
$7.10
52-Week Range:
$5.275
$14.84
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
6.43 | 457.33M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - The Manila Times
When Will Altimmune Report Q4 Earnings? Key Date and Details for Biotech Investors - StockTitan
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH - Seeking Alpha
Investigation announced for Long-Term Investors in shares - openPR
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune (NASDAQ:ALT) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy on Altimmune stock, $12 target - MSN
Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
BlackRock, Inc.'s Strategic Acquisition of Altimmune Inc Shares - GuruFocus.com
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns - Yahoo Finance
IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average PT from Analysts - MarketBeat
Exchange Traded Concepts LLC Cuts Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
HC Wainwright Weighs in on Altimmune FY2029 Earnings - MarketBeat
JPMorgan Chase & Co. Decreases Holdings in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP ... - The Bakersfield Californian
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages - EIN News
(ALT) Technical Pivots with Risk Controls - Stock Traders Daily
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Altimmune Management Reveals Strategic Roadmap at Major Biotech Conference - StockTitan
HC Wainwright Forecasts Altimmune FY2029 Earnings - MarketBeat
Altimmune spikes after presenting data for obesity drug - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Australia
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - MSN
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune's (ALT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Drugs - Morningstar
Long Term Trading Analysis for (ALT) - Stock Traders Daily
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Altimmune stock at Buy on pemvidutide potential - Investing.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
| Roberts M Scot | Chief Scientific Officer |
Jan 25 '25 |
Option Exercise |
0.00 |
14,600 |
0 |
57,910 |
| Jordt Raymond M | Chief Business Officer |
Jan 25 '25 |
Option Exercise |
0.00 |
14,600 |
0 |
36,150 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):